Pimocard is a prescription medication indicated for the management of the signs associated with congestive heart failure in dogs. It is commonly prescribed in clinical scenarios that involve myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM). The medication is part of a comprehensive care plan intended to help support cardiac function. This use may be associated with improved comfort and quality of life for the patient.

The drug is approved for the management of the signs of mild, moderate, or severe congestive heart failure due to clinical myxomatous mitral valve disease or dilated cardiomyopathy. “The overall goal of this therapeutic support is to help ease the symptomatic burden of the heart condition.”

---

Quick Fact: Relief for Signs of Congestive Heart Failure

Regulatory References

1. FDA Freedom of Information Summary

Official Eligibility and Restrictions

The eligibility for Pimocard (Pimobendan) is strictly defined by regulatory labeling for its use as a cardiac medicine in dogs. Use is permitted for dogs diagnosed with Myxomatous Mitral Valve Disease (MMVD) or Dilated Cardiomyopathy (DCM), presenting with signs of congestive heart failure. Specific formulations are also authorized for Stage B2 preclinical MMVD, which involves asymptomatic dogs with documented cardiomegaly.

Absolute Contraindications

The medicine is strictly contraindicated and must not be used in dogs with Hypertrophic Cardiomyopathy (HCM), Aortic Stenosis, or any condition where increasing cardiac output is functionally or anatomically inappropriate. Use is also prohibited for dogs with severe impairment of liver function (hepatic insufficiency) and those with a known hypersensitivity to the active substance.

Restricted and Non-Established Use

Regulatory bodies have stated that safe use has not been established or not been evaluated in several populations. These groups include dogs younger than six months of age, dogs with congenital heart defects, and those with diabetes mellitus or other serious metabolic diseases. Use in pregnant or lactating bitches is generally not recommended due to a lack of established safety data in these populations.

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Pimocard (Pimobendan) as stated in government regulatory labeling, such as the Summary of Product Characteristics (SmPC) and Prescribing Information.

Documented Drug-Drug and Drug-Food Interactions

The interaction profile includes pharmacodynamic (PD) and pharmacokinetic (PK) constraints:

• Pharmacodynamic Attenuation: Co-administration with certain cardioactive medicinal products is documented to lessen the positive inotropic effect of Pimobendan. Specifically, beta-antagonists and calcium antagonists (such as Verapamil or Diltiazem) may attenuate the drug's effect on cardiac contractility. The official labeling, however, states that co-administration with diuretics (e.g., Furosemide) is permissible and common.
• Pharmacokinetic Drug-Food Interaction: Regulatory data indicates that the drug's bioavailability is considerably reduced when administered with food. To mitigate this PK effect, a timing-based constraint requires that each dose be administered approximately one hour before feeding.

Population-Specific Restriction

Official labeling contains a restriction tied to the drug’s clearance pathway. Since Pimobendan is metabolized predominantly by the liver, its use is formally contraindicated in patients with severe impairment of liver function.

Modulation of Contractile Efficiency (Positive Inotropy)

This domain covers the unique interaction of Pimobendan with the muscle fibers of the heart. The mechanism, known as calcium sensitization, increases the responsiveness of Cardiac Troponin C to available calcium, leading to a more forceful contraction and improved utilization of calcium, which produces the physiological consequence of positive inotropy.

Regulation of Vascular Tone (Vasodilation)

This mechanistic block involves the drug's action outside the heart, where it modulates key enzyme systems. By inhibiting Phosphodiesterase type III (PDE III) in vascular smooth muscle, the drug alters the cAMP signaling pathway to promote vessel relaxation, which produces balanced vasodilation and the physiological consequence of reduced resistance and volume load on the ventricles.

Integrated Dual-Action Synergy and Systemic Consequences

The integration of enhanced contractile strength and simultaneous load reduction defines the medication's dual mechanism. This synergy of effects results in a sustained enhancement of hemodynamic function. This improved hemodynamic status results in a reduction in the signaling intensity of maladaptive systems like the Renin-Angiotensin-Aldosterone System (RAAS) and Sympathetic Nervous System (SNS), which shapes the resulting downstream neurohormonal activity.

The administration of Pimocard follows specific instructions defining the required dose, frequency, and relationship to feeding time. The medication is intended for chronic, often life-long, management.

Administration Scope

Entity	Instruction
Route of administration	Oral use only, available as chewable tablets or an oral solution.
Dosing schedule	The total daily dose is set at 0.5 mg of Pimobendan per kilogram (kg) of body weight.
Timing in relation to meals	Each dose must be administered approximately one hour before feeding to optimize the uptake of the active substance.
Frequency and timing	The total daily dose must be divided into two portions and given approximately 12 hours apart (twice daily).
Preparation requirements	Chewable tablets are scored and may be halved to achieve the dose accurate to the nearest half-tablet increment. Oral solutions require precise measurement using the provided syringe.
Missed-dose rule	If an administration is missed, the user should wait until the next scheduled dosing time and resume the normal pattern; a double dose should not be administered.

Procedural Structure

The procedure is defined by the following sequence:

1. The total daily dose is calculated based on the 0.5 mg/kg rule and then divided into two portions.
2. The first portion is administered orally, approximately 60 minutes before the morning meal.
3. The second portion is administered orally, approximately 60 minutes before the evening meal, maintaining the 12-hour interval.

The structure of these instructions ensures a consistent twice-daily dose is delivered on an empty stomach, which is necessary to maintain the therapeutic regimen for chronic cardiac support.

Research evidence / Overview of studies for Pimocard

---

Evidence for Symptom Management in Congestive Heart Failure

Research was evaluated in studies exploring the management of dogs showing clinical signs of congestive heart failure (CHF) due to Myxomatous Mitral Valve Disease (MMVD) or Dilated Cardiomyopathy (DCM). These studies monitored dogs receiving Pimocard alongside other established heart failure medications. Outcomes studied included overall survival time and time to heart failure progression. The evidence remains limited regarding its evaluation when used alone, as the majority of trials studied its use as an addition to other standard therapies.

Evidence for Delaying CHF Onset in MMVD (Stage B2)

The research was evaluated in a single, large-scale, international randomized controlled trial, examining asymptomatic dogs with MMVD and objective signs of significant heart enlargement. Researchers monitored the time to a composite endpoint of clinical CHF onset or cardiac death. The study design included predefined criteria for early cessation based on interim analysis of the observed patterns. Results apply only to the populations studied who meet specific measurement criteria for heart enlargement; evidence is limited for dogs with MMVD who do not meet these specific size criteria.

Research on Disease Progression in Preclinical DCM

Research was evaluated in randomized, placebo-controlled trials specifically on high-risk breeds (such as Doberman Pinschers) with preclinical DCM. Researchers monitored time to a composite endpoint that included the onset of CHF or sudden death, and the findings describe measurements of the time to this combined event. Evidence is limited for applying these findings to other breeds. Furthermore, when the separate outcome of sudden death was analyzed, the findings were inconclusive, and certainty remains low regarding its independent role.

Areas of Uncertainty and Research Gaps

Long-term effects are not fully established beyond the observation periods of the main studies, as follow-up durations were limited in providing a complete picture of the full lifespan impact. Data for certain patient groups, such as those with complex comorbidities, remain insufficient. Research does not determine whether an individual will respond similarly to the group patterns observed under specific trial conditions.

Key Studies & References

1. FDA Freedom of Information Summary: Vetmedin (Pimobendan) Original Application (Symptomatic CHF)

Common questions about Pimocard (FAQ)

Q: Can Pimocard be stopped suddenly, or is tapering necessary?

Official product information describes Pimocard as a medicine intended for chronic, often life-long administration for cardiac support. Regulatory documents do not contain a specific instruction regarding the procedure for stopping the use of the medicine, such as a requirement for gradual reduction.

Q: Does Pimocard cause weight changes?

According to the official safety data and adverse reactions lists, changes in body weight (gain or loss) are not listed as documented common or uncommon adverse reactions observed in clinical studies. The official documents focus on effects like vomiting, diarrhea, and lethargy.

Q: Is it safe to take Pimocard if I have kidney issues?

Regulatory documents contain an explicit prohibition for use in patients with severe impairment of liver function. The official product labeling does not, however, list kidney impairment as an absolute contraindication for use.

Q: Can women who are planning pregnancy take Pimocard?

Use of Pimocard in pregnant or nursing (lactating) populations is generally not recommended by regulatory bodies due to a lack of established safety data in these specific groups. This absence of safety data also applies to the period when a patient is actively planning pregnancy.

Q: Are there any known long-term effects of Pimocard on organs like the kidneys or liver?

The official labeling contains a restriction that prohibits use in patients with severe liver impairment. Studies have noted specific cardiac pathologies, such as myxomatous thickening of the mitral valves, following long-term exposure at doses exceeding the therapeutic recommendation.

Q: How quickly does Pimocard start working after I begin taking it?

Pharmacokinetic data from official regulatory sources indicate that the active substance reaches its maximum concentration in the blood approximately one hour after administration.

Q: Why do some people say they feel tired when they take Pimocard?

The official safety data for Pimocard lists 'Lethargy' as a commonly observed adverse reaction reported in clinical studies. This medical term aligns with what users may describe as feeling tired or sluggish.

Q: Can drinking caffeine affect how Pimocard works?

Official regulatory documents that describe drug interactions do not formally document a specific interaction between Pimocard and caffeine.

Q: Is Pimocard safe for elderly patients?

Official documents define specific safety constraints for very young patients (under six months of age). The product labeling does not establish specific dose adjustments or safety constraints for elderly patients based solely on advanced age.

Q: What is the general age range for people who are prescribed Pimocard?

The product labeling states that safe use has not been established for patients younger than six months of age. There is no specific upper age limit established by regulatory bodies.

Q: Is it true that Pimocard should not be taken with grapefruit juice?

No specific interaction with grapefruit juice is formally documented in the official regulatory labeling information for Pimocard.

Q: Is Pimocard a controlled substance?

According to official regulatory scheduling documentation, Pimocard (Pimobendan) is not classified as a controlled substance.

Q: Does Pimocard make people feel depressed or anxious?

Depression or anxiety are not listed as documented common or uncommon adverse reactions in the official regulatory safety documents.

Q: Can I take Pimocard if I am scheduled for surgery?

Official documents do not contain specific public guidance regarding the use of Pimocard immediately before or after a surgical procedure.

Q: How does Pimocard relate to the use of alcohol?

No specific interaction or public warning related to the simultaneous consumption of alcohol is formally documented in the official labeling.

Q: Are Pimocard's side effects different for men and women?

Summaries of official clinical trials do not indicate significant differences in the frequency or nature of side effects based on patient sex.

Q: Has Pimocard been recalled anywhere in the world?

A review of official regulatory history and public health action records does not indicate any product recall for Pimocard.

Q: Does Pimocard interact with any common vitamins?

Official regulatory documents detailing drug interactions do not formally document a specific interaction between Pimocard and common vitamins.

Q: Is a low blood pressure reading normal when taking Pimocard?

Pimocard is known to have a vasodilatory effect, meaning it helps relax blood vessels and reduce resistance. This physiological consequence can lead to a drop in blood pressure.

Q: What is the half-life of Pimocard, generally speaking?

Official pharmacokinetic data describes the elimination half-life of Pimobendan as approximately 0.4 hours. Its active metabolite has an elimination half-life of approximately 2 hours.

Q: Does taking Pimocard affect driving or operating machinery?

Official labeling does not contain a specific caution about operating machinery, but the potential for lethargy is documented as a common adverse reaction.

Q: What is the significance of the black box warning (if any) on Pimocard?

Pimocard is not currently required to carry a Boxed Warning (often called a Black Box Warning) as defined by the official regulatory documents.

Q: Where can I find the official FDA patient information leaflet for Pimocard?

The official FDA Prescribing Information and patient-friendly drug information are publicly available and can be found on the DailyMed website, which is managed by the NIH (National Institutes of Health).

Storage Conditions and Stability

The product must be stored at a controlled room temperature, typically not above 30 C (86 F), to maintain stability. Pimocard should be kept in its original container to protect it from moisture and light, and the container should be tightly closed.

If a tablet is divided or halved, the unused portion must be immediately returned to the opened blister pocket and used within 3 days.

Child and Animal Safety

Official labeling requires that Pimocard be stored out of the sight and reach of children and out of reach of animals at all times due to the tablet's flavoring.

Disposal Instructions

Unused or expired medicinal product must not be disposed of via wastewater or household waste. Disposal must be carried out in accordance with local regulatory requirements and applicable national collection schemes.